- Home
- GUTS vs EDAP Comparison
GUTS vs EDAP Comparison
Compare GUTS & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- EDAP
- Stock Information
- Founded
- GUTS 2010
- EDAP 1979
- Country
- GUTS United States
- EDAP France
- Employees
- GUTS N/A
- EDAP N/A
- Industry
- GUTS
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- GUTS
- EDAP Health Care
- Exchange
- GUTS NYSE
- EDAP Nasdaq
- Market Cap
- GUTS 58.8M
- EDAP 53.8M
- IPO Year
- GUTS 2024
- EDAP 1997
- Fundamental
- Price
- GUTS $1.58
- EDAP $1.67
- Analyst Decision
- GUTS Buy
- EDAP Buy
- Analyst Count
- GUTS 1
- EDAP 3
- Target Price
- GUTS $10.00
- EDAP $8.50
- AVG Volume (30 Days)
- GUTS 930.5K
- EDAP 37.9K
- Earning Date
- GUTS 08-13-2025
- EDAP 05-15-2025
- Dividend Yield
- GUTS N/A
- EDAP N/A
- EPS Growth
- GUTS N/A
- EDAP N/A
- EPS
- GUTS N/A
- EDAP N/A
- Revenue
- GUTS $60,000.00
- EDAP $67,840,467.00
- Revenue This Year
- GUTS N/A
- EDAP N/A
- Revenue Next Year
- GUTS N/A
- EDAP N/A
- P/E Ratio
- GUTS N/A
- EDAP N/A
- Revenue Growth
- GUTS N/A
- EDAP 3.69
- 52 Week Low
- GUTS $0.87
- EDAP $1.26
- 52 Week High
- GUTS $4.92
- EDAP $5.46
- Technical
- Relative Strength Index (RSI)
- GUTS 42.52
- EDAP 35.49
- Support Level
- GUTS $1.54
- EDAP $1.60
- Resistance Level
- GUTS $1.82
- EDAP $1.80
- Average True Range (ATR)
- GUTS 0.18
- EDAP 0.10
- MACD
- GUTS -0.07
- EDAP -0.01
- Stochastic Oscillator
- GUTS 5.06
- EDAP 8.00
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.